Pancreatic Cancer Research

ResearcherYamaguchi UniversityNo recent work listed

Nobuaki Suzuki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8391-2395; OpenAlex author ID A5034063496. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper

Papers 13

  1. Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study. Co-author DOI 10.21873/invivo.13380↗
  2. Hepatic artery resection and reconstruction using the right gastroepiploic artery during pancreaticoduodenectomy in advanced pancreatic cancer. Co-author DOI 10.1007/s00423-021-02120-0↗
  3. Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Co-author DOI 10.1097/mpa.0000000000001772↗
  4. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Co-author DOI 10.3892/ol.2020.12291↗
  5. Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection. Co-author DOI 10.1097/mcg.0000000000000551↗
  6. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Co-author DOI 10.1097/mpa.0000000000000880↗
  7. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  8. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  9. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy]. Co-author PMID 28133195↗
  10. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000012↗
  11. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Co-author DOI 10.1186/1479-5876-12-175↗
  12. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. Co-author DOI 10.3892/ijo.2014.2603↗
  13. Proteomic differential display identifies upregulated vinculin as a possible biomarker of pancreatic cancer. Co-author DOI 10.3892/or.2012.2004↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshitaro Shindo · 12 shared papers, 2014–2023 · strength 0.90
  2. Hiroto Matsui Matsui · 11 shared papers, 2014–2023 · strength 0.87
  3. Hiroaki Nagano · 8 shared papers, 2016–2023 · strength 0.74
  4. Satoshi Matsukuma · 5 shared papers, 2016–2021 · strength 0.46
  5. Masao Nakajima · 3 shared papers, 2017–2023 · strength 0.37
  6. Tomio Ueno · 8 shared papers, 2012–2017 · strength 0.37
  7. Masaaki Oka · 7 shared papers, 2012–2017 · strength 0.29
  8. Tatsuya Ioka · 2 shared papers, 2021–2023 · strength 0.28
  9. Ryouichi Tsunedomi · 3 shared papers, 2014–2021 · strength 0.25
  10. Yasuhiro Fujiwara · 2 shared papers, 2021 · strength 0.22
  11. Takuya Fujimoto · 2 shared papers, 2016–2021 · strength 0.16
  12. Hidetoshi Eguchi · 1 shared paper, 2021 · strength 0.11
  13. Haruo Iguchi · 2 shared papers, 2017 · strength 0.09
  14. Takashi Hatori · 2 shared papers, 2017 · strength 0.09
  15. Tetsuya Ikemoto · 2 shared papers, 2017 · strength 0.09
  16. Yuzo Umeda · 2 shared papers, 2017 · strength 0.09
  17. Mitsuo Shimada · 2 shared papers, 2017 · strength 0.09
  18. Yusuke Nakamura · 2 shared papers, 2017 · strength 0.09
  19. Toshiyoshi Fujiwara · 2 shared papers, 2017 · strength 0.09
  20. Hiroaki Nagano · 1 shared paper, 2017 · strength 0.05
  21. Kosei Hirakawa · 1 shared paper, 2017 · strength 0.05
  22. Yutaka Suehiro · 1 shared paper, 2014 · strength 0.04
  23. Takahiro Yamasaki · 1 shared paper, 2014 · strength 0.04
  24. Yusaku Watanabe · 1 shared paper, 2014 · strength 0.03
  25. Koji Tamada · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.